Metastatic gastric cancer (MGC) patients

Can we improve survival by metastasectomy? A systematic review and meta-analysis

Rahul Gadde, Leonardo Tamariz, Mena Hanna, Eli Avisar, Alan Livingstone, Dido Franceschi, Danny Yakoub

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background Prognosis with current management strategies continues to be dismal in metastatic gastric cancer (MGC) patients. We aimed to evaluate the role of metastasectomy in improving survival. Methods A comprehensive search of MEDLINE, EMBASE, SCOPUS, and Cochrane central databases (1965 to present) was performed. All comparative studies measuring survival in MGC patients undergoing metastasectomy versus other therapies were included. Pooled risk ratios with corresponding 95% confidence intervals (CI) were calculated for survival at 1, 3, and 5 years. Results Sixteen studies with 1712 patients (378 patients in metastasectomy, 1334 patients in other therapies) were eligible for the final meta-analysis. Median age was 63 years. For patients undergoing metastasectomy, a significant survival advantage was observed at 1 year (RR 0.52, CI 0.43-0.62), 3 year (RR 0.75 CI 0.67-0.83), and 5 year (RR 0.82, CI 0.74-0.91); mean increased difference in survival conferred by metastasectomy averaged between 9.3 and 15.7 months; P < 0.001 for all results. Age, ECOG status, and STROBE score did not contribute to differences in survival. Conclusion Metastasectomy is associated with increased survival at 1, 3, and 5 years in MGC patients. Large prospective randomized controlled trials are critically needed to evaluate the role of metastasectomy in MGC. J. Surg. Oncol. 2015 111:38-45.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal of Surgical Oncology
Volume112
Issue number1
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Metastasectomy
Stomach Neoplasms
Meta-Analysis
Survival
Confidence Intervals
MEDLINE
Randomized Controlled Trials
Odds Ratio
Databases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Metastatic gastric cancer (MGC) patients : Can we improve survival by metastasectomy? A systematic review and meta-analysis. / Gadde, Rahul; Tamariz, Leonardo; Hanna, Mena; Avisar, Eli; Livingstone, Alan; Franceschi, Dido; Yakoub, Danny.

In: Journal of Surgical Oncology, Vol. 112, No. 1, 01.07.2015, p. 38-45.

Research output: Contribution to journalArticle

Gadde, Rahul ; Tamariz, Leonardo ; Hanna, Mena ; Avisar, Eli ; Livingstone, Alan ; Franceschi, Dido ; Yakoub, Danny. / Metastatic gastric cancer (MGC) patients : Can we improve survival by metastasectomy? A systematic review and meta-analysis. In: Journal of Surgical Oncology. 2015 ; Vol. 112, No. 1. pp. 38-45.
@article{0dee35ab2b374246be8b5bd2d7167d19,
title = "Metastatic gastric cancer (MGC) patients: Can we improve survival by metastasectomy? A systematic review and meta-analysis",
abstract = "Background Prognosis with current management strategies continues to be dismal in metastatic gastric cancer (MGC) patients. We aimed to evaluate the role of metastasectomy in improving survival. Methods A comprehensive search of MEDLINE, EMBASE, SCOPUS, and Cochrane central databases (1965 to present) was performed. All comparative studies measuring survival in MGC patients undergoing metastasectomy versus other therapies were included. Pooled risk ratios with corresponding 95{\%} confidence intervals (CI) were calculated for survival at 1, 3, and 5 years. Results Sixteen studies with 1712 patients (378 patients in metastasectomy, 1334 patients in other therapies) were eligible for the final meta-analysis. Median age was 63 years. For patients undergoing metastasectomy, a significant survival advantage was observed at 1 year (RR 0.52, CI 0.43-0.62), 3 year (RR 0.75 CI 0.67-0.83), and 5 year (RR 0.82, CI 0.74-0.91); mean increased difference in survival conferred by metastasectomy averaged between 9.3 and 15.7 months; P < 0.001 for all results. Age, ECOG status, and STROBE score did not contribute to differences in survival. Conclusion Metastasectomy is associated with increased survival at 1, 3, and 5 years in MGC patients. Large prospective randomized controlled trials are critically needed to evaluate the role of metastasectomy in MGC. J. Surg. Oncol. 2015 111:38-45.",
author = "Rahul Gadde and Leonardo Tamariz and Mena Hanna and Eli Avisar and Alan Livingstone and Dido Franceschi and Danny Yakoub",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/jso.23945",
language = "English (US)",
volume = "112",
pages = "38--45",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Metastatic gastric cancer (MGC) patients

T2 - Can we improve survival by metastasectomy? A systematic review and meta-analysis

AU - Gadde, Rahul

AU - Tamariz, Leonardo

AU - Hanna, Mena

AU - Avisar, Eli

AU - Livingstone, Alan

AU - Franceschi, Dido

AU - Yakoub, Danny

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background Prognosis with current management strategies continues to be dismal in metastatic gastric cancer (MGC) patients. We aimed to evaluate the role of metastasectomy in improving survival. Methods A comprehensive search of MEDLINE, EMBASE, SCOPUS, and Cochrane central databases (1965 to present) was performed. All comparative studies measuring survival in MGC patients undergoing metastasectomy versus other therapies were included. Pooled risk ratios with corresponding 95% confidence intervals (CI) were calculated for survival at 1, 3, and 5 years. Results Sixteen studies with 1712 patients (378 patients in metastasectomy, 1334 patients in other therapies) were eligible for the final meta-analysis. Median age was 63 years. For patients undergoing metastasectomy, a significant survival advantage was observed at 1 year (RR 0.52, CI 0.43-0.62), 3 year (RR 0.75 CI 0.67-0.83), and 5 year (RR 0.82, CI 0.74-0.91); mean increased difference in survival conferred by metastasectomy averaged between 9.3 and 15.7 months; P < 0.001 for all results. Age, ECOG status, and STROBE score did not contribute to differences in survival. Conclusion Metastasectomy is associated with increased survival at 1, 3, and 5 years in MGC patients. Large prospective randomized controlled trials are critically needed to evaluate the role of metastasectomy in MGC. J. Surg. Oncol. 2015 111:38-45.

AB - Background Prognosis with current management strategies continues to be dismal in metastatic gastric cancer (MGC) patients. We aimed to evaluate the role of metastasectomy in improving survival. Methods A comprehensive search of MEDLINE, EMBASE, SCOPUS, and Cochrane central databases (1965 to present) was performed. All comparative studies measuring survival in MGC patients undergoing metastasectomy versus other therapies were included. Pooled risk ratios with corresponding 95% confidence intervals (CI) were calculated for survival at 1, 3, and 5 years. Results Sixteen studies with 1712 patients (378 patients in metastasectomy, 1334 patients in other therapies) were eligible for the final meta-analysis. Median age was 63 years. For patients undergoing metastasectomy, a significant survival advantage was observed at 1 year (RR 0.52, CI 0.43-0.62), 3 year (RR 0.75 CI 0.67-0.83), and 5 year (RR 0.82, CI 0.74-0.91); mean increased difference in survival conferred by metastasectomy averaged between 9.3 and 15.7 months; P < 0.001 for all results. Age, ECOG status, and STROBE score did not contribute to differences in survival. Conclusion Metastasectomy is associated with increased survival at 1, 3, and 5 years in MGC patients. Large prospective randomized controlled trials are critically needed to evaluate the role of metastasectomy in MGC. J. Surg. Oncol. 2015 111:38-45.

UR - http://www.scopus.com/inward/record.url?scp=84937509522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937509522&partnerID=8YFLogxK

U2 - 10.1002/jso.23945

DO - 10.1002/jso.23945

M3 - Article

VL - 112

SP - 38

EP - 45

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -